Gefitinib, a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for EGFR-mutant lung cancers due to its effectiveness in the initial treatment phase [10]. Here, EGFR is linked to lung carcinoma.